Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin

Amparo Santamaría(Hospital de Sant Pau), Salut Brunet(Institut Català d'Oncologia), Rodrigo Martino(Universitat Autònoma de Barcelona), Eduardo Muñiz‐Díaz(Banc de Sang i Teixits), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), A Domingo-Albós(Clínica Rementería)
Bone Marrow Transplantation
December 1, 1997
10.1038/sj.bmt.1701012
Cited by 42

Related Papers

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2015|740
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2023|538
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532